Custom Antibody Production, CAR-T Services, mRNA-LNP
mRNA-LNP Development
Completely validated mRNA-LNP platform—services include formulation & manufacturing
CAR-T/NK Development
CRO/CDMO services covering early discovery through to clinical trials
Antibody Engineering & Production
Flexible services focused on therapeutic applications
Fueling A New Era In Medicine
Since 2001, ProMab has built in-house expertise in the latest technologies to help our partners push the frontiers of medicine.
Today, we are the only provider that can offer CAR-T/NK development, mRNA-LNP development, and antibody engineering: highly promising technologies on their own and even more powerful when combined.
Turn tumors into cancer vaccines, manufacture antibodies in the body, revolutionize cancer care... imagine the possibilities and we'll help you bring them to life.
5,000+
monoclonal antibodies generated
50+
filed patents
500+
CAR-T projects finished
4
Phase 2 clinical trials started
Services
CAR-T/CAR-NK Development
mRNA-Lipid Nanoparticle Development
Leverage our validated platform to advance your studies into the use of LNP-based delivery of mRNAs, including the development of vaccines, engineered immune cells, or antibody-encoding mRNA solutions.
Cell-Based Assays
Protein Expression Services
Featured Publications
Intratumoral injection of EpCAM BITE, IL-12, and GM-CSF mRNA-LNPs blocks the growth of local treated and distant untreated tumors Proc Natl Acad Sci U S A. 2026 Sep 8; 123(36): e2616059123.
HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth Vaccines (Basel). 2024 Jul 21; 12(7): 808.
CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo Int J Mol Sci. 2023 Aug 29; 24(17): 13364.
